Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227124 | 0.87 | MAPK1 (0.44) | ALDH1A1MAPK1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL1227710 | 0.87 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2GBA1POLB | |
| SCHEMBL1227845 | 0.82 | MAPK1 (0.45) | ALDH1A1MAPK1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL1227827 | 0.82 | HPGD (0.43) | ALDH1A1MAPK1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL1227596 | 0.82 | TSHR (0.41) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1227916 | 0.82 | TSHR (0.41) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1227985 | 0.82 | HPGD (0.43) | ALDH1A1MAPK1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL1227725 | 0.82 | LMNA (0.47) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1226460 | 0.81 | PSIP1 (0.42) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL1226481 | 0.80 | MAPT (0.38) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | claimed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | claimed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | claimed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | claimed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | claimed |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | ALDH1A1 3260/4885MAPK1 2348/4885MAPT 2788/4885 |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | ALDH1A1 3260/4885MAPK1 2348/4885MAPT 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.